Improving early detection of liver cancer using biomarker screening algorithms
Biomarker screening algorithms for the improved early detection of hepatocellular carcinoma
This study is working on new blood tests to help find liver cancer earlier, so patients can get treatment sooner and have better chances of recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11064014 on NIH RePORTER |
What this research studies
This research focuses on developing new algorithms to enhance the early detection of hepatocellular carcinoma (HCC), a type of liver cancer that is often diagnosed at an advanced stage. The study aims to create and evaluate innovative biomarker screening methods that utilize blood tests to identify HCC earlier than current practices allow. By analyzing multiple biomarkers, including alpha-fetoprotein and other promising candidates, the research seeks to establish personalized thresholds for better detection rates. This approach could lead to more patients receiving timely treatment options, potentially improving their outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for hepatocellular carcinoma, such as those with cirrhosis or chronic liver disease.
Not a fit: Patients who do not have liver disease or are not at risk for hepatocellular carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce mortality rates from liver cancer by enabling earlier diagnosis and treatment.
How similar studies have performed: Previous research has shown promise in using biomarker screening for early cancer detection, indicating that this approach could be effective.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Tayob, Nabihah — Dana-Farber Cancer Inst
- Study coordinator: Tayob, Nabihah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.